Nasdaq · CIK 0001768224
ARCT Arcturus Therapeutics Holdings Inc.
Insider trading from SEC Form 4. Last filing Aug 20, 2025. Close $13.74 on Oct 9, 2026, +148% from the 52-week low and -41% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
ARCTOct 9, 2026 · close 13.74
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Arcturus Therapeutics Holdings Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Andy Sassine Chief Financial Officer buy | $20k 1,238 shares | +1% | +119% from low-24% from high | |
| 21Weak | Andy Sassine Chief Financial Officer buy | $20k 1,238 shares | +1% | +119% from low-24% from high | |
| 13Weak | Pad Chivukula Chief Scientific Officer & COO sell | $249k 12,000 shares | -3% | - |
Transactions
The last 14 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 15, 2025 | Andy Sassine Chief Financial Officer | POpen-market purchase Common Stock | +1,238 | $16.56 | $20k | 221,764 | Aug 20, 2025 |
| Aug 15, 2025 | Andy Sassine Chief Financial Officer | POpen-market purchase Common Stock | -1,238 | $16.56 | $20k | 221,764 | Aug 19, 2025 |
| Jun 9, 2025 | Edward W Holmes director | AGrant or award Stock option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 11, 2025 |
| Jun 9, 2025 | James F Barlow director | AGrant or award Stock option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 11, 2025 |
| Jun 9, 2025 | Jing L. Marantz director | AGrant or award Stock option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 11, 2025 |
| Jun 9, 2025 | John Markels director | AGrant or award Stock option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 11, 2025 |
| Jun 9, 2025 | Magda Marquet director | AGrant or award Stock option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 11, 2025 |
| Jun 9, 2025 | Moncef Slaoui director | AGrant or award Stock option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 11, 2025 |
| Jun 9, 2025 | Peter C Farrell director | AGrant or award Stock option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 11, 2025 |
| Dec 16, 2024 | Andy Sassine Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Dec 18, 2024 |
| Dec 16, 2024 | Pad Chivukula Chief Scientific Officer & COO | AGrant or award Employee Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Dec 18, 2024 |
| Dec 16, 2024 | Joseph E Payne President and CEO | AGrant or award Employee Stock Option (right to buy)derivative | +196,000 | $0.00 | $0 | 196,000 | Dec 18, 2024 |
| Dec 16, 2024 | Lance Kurata Chief Legal Officer | AGrant or award Employee Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Dec 18, 2024 |
| Oct 15, 2024 | Pad Chivukula Chief Scientific Officer & COO | SOpen-market sale Common Stock10b5-1 | -12,000 | $20.76 | $249k | 435,334 | Oct 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- James F Barlowdirector
- Pad ChivukulaChief Scientific Officer & COO
- Peter C Farrelldirector
- Edward W Holmesdirector
- Lance KurataChief Legal Officer
- Jing L. Marantzofficer, director
- John Markelsdirector
- Magda Marquetdirector
- Joseph E PaynePresident and CEO
- Andy SassineChief Financial Officer
- Moncef Slaouidirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.